Analysts’ Top Technology Picks: PaySign (PAYS), MinebeaMitsumi (MNBEF)
This article highlights two technology stocks, PaySign (PAYS) and MinebeaMitsumi (MNBEF), that have recently received bullish ratings from analysts. Barrington analyst Gary Prestopino maintained a Buy rating on PaySign, citing an average price target of $9.50, while Goldman Sachs analyst Daiki Takayama maintained a Buy rating on MinebeaMitsumi with a price target of Yen5500.00. Both companies are seen as strong investment opportunities within the technology sector.
Price to book forward of Paysign, Inc. – NASDAQ:PAYS
This page from TradingView displays financial information for Paysign, Inc. (NASDAQ: PAYS), specifically focusing on its Price to Book Forward metric. The content indicates that the financial data is provided by reputable sources like ICE Data Services and FactSet, highlighting the company's valuation within the commercial services sector.
Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results; Patient Affordability Drives 40% Revenue Growth and Significant Margin Expansion
Paysign, Inc. (NASDAQ: PAYS) announced strong financial results for the fourth quarter and full-year 2025, driven by significant growth in its patient affordability offerings. The company reported a 40.5% increase in full-year revenue to $82.0 million and a 107.3% increase in Adjusted EBITDA to $19.94 million. Paysign also provided an optimistic outlook for 2026, forecasting continued revenue growth and improved operating leverage due to expanding presence in the life sciences ecosystem.
Paysign Insider Sold Shares Worth $801,140, According to a Recent SEC Filing
An insider at Paysign (PAYS) sold shares totaling $801,140, according to a recent SEC filing. The company is a provider of prepaid card programs, patient affordability offerings, digital banking services, and integrated payment processing. Paysign's solutions are designed for businesses, consumers, and government institutions, utilizing its payment platform for various digital payout solutions.
Form 4 Paysign Inc For: 30 June By Investing.com
This article from Investing.com is a brief report on a Form 4 filing for Paysign Inc. for the period ending June 30. It includes a stock ticker for PAYS and notes a 3.50% decrease. The content primarily focuses on market data and other news rather than details about the Form 4.
Paysign EVP Joan M Herman sells $801,140 in company stock By Investing.com
Paysign's Executive Vice President of Operations, Joan M Herman, sold 100,000 shares of the company's common stock for over $800,000 on June 26, 2026, under a Rule 10b5-1 trading plan. This sale occurred after a significant 59% surge in Paysign's stock over the past six months. Separately, Paysign reported strong Q1 2026 results, exceeding revenue and EPS forecasts, which led to DA Davidson reiterating a Buy rating with a $9.00 price target.
Paysign (PAYS) EVP sells 100,000 shares in pre-set 10b5-1 stock plan
Paysign, Inc.'s EVP of Operations, Joan M. Herman, sold 100,000 shares of common stock at a weighted average price of $8.0114 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025. Following the sale, Herman still directly holds 707,009 shares, indicating a routine liquidity transaction rather than a change in market outlook.
Paysign EVP Joan M Herman sells $801,140 in company stock By Investing.com
Paysign EVP Joan M Herman sold 100,000 shares of company stock worth $801,140 on June 26, 2026, under a Rule 10b5-1 trading plan. This transaction occurred after Paysign's stock surged nearly 59% in six months, though InvestingPro analysis indicates it is currently overvalued. The company recently reported strong first-quarter 2026 results, exceeding revenue and EPS forecasts, leading DA Davidson to reiterate a Buy rating.
Enterprise value to EBITDA forward of Paysign, Inc. – BOATS:PAYS
This article provides financial data, specifically the Enterprise Value to EBITDA forward ratio, for Paysign, Inc. (PAYS) through the BOATS (Blue Ocean Alternative Trade System) platform on TradingView. It indicates that the market was closed at the time of publication and gives no specific values, but focuses on the availability of this financial metric.
Enterprise value to EBIT forward of Paysign, Inc. – BOATS:PAYS
This article provides an analysis of Paysign, Inc. (PAYS) focusing on its enterprise value to EBIT forward ratio. The content is presented within the context of financial data and market performance on the TradingView platform.
Price to earnings forward of Paysign, Inc. – NASDAQ:PAYS
This page provides financial information for Paysign, Inc. (NASDAQ: PAYS), specifically focusing on its forward price-to-earnings ratio. It indicates that the market is closed with no trades recorded and that the content is provided by TradingView, with data from ICE Data Services and FactSet.
Paysign, Inc. Actuals & Estimates (NASDAQ:PAYS)
This article provides an overview of Paysign, Inc. (NASDAQ: PAYS) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue for recent quarters, and highlights the company's market capitalization and upcoming earnings date. The article also addresses frequently asked questions regarding PAYS stock's volatility, dividend policy, employee count, and how to buy its shares.
Paysign, Inc. Actuals & Estimates (BOATS:PAYS)
This article provides an overview of Paysign, Inc. (PAYS) financial actuals and estimates. It covers analyst price targets, historical stock performance, upcoming earnings reports, and key financial metrics like earnings per share, revenue, net income, EBITDA, and employee count. The article also confirms that Paysign, Inc. does not pay dividends.
PAYS Forecast — Price Target — Prediction for 2027
This article provides a forecast for Paysign, Inc. (PAYS) stock, including analyst price targets and predictions, with a maximum estimate of $12.75 and a minimum of $8.50. It details the company's past earnings performance, revenue, net income, and upcoming earnings report date of August 11, 2026. Additionally, it offers information on PAYS's historical stock prices, employee count, and EBITDA.
Paysign’s (PAYS) Quarterly Results Defy Disruption Fears
Paysign, Inc. (NASDAQ:PAYS) reported strong Q4 2025 earnings, beating expectations and raising 2026 guidance, which helped alleviate previous fears related to AI disruption and pharmaceutical industry changes. Despite prior underperformance, the financial technology company's stock has shown significant growth over the past year, and it continues to be valued attractively at 7x EV/EBITDA while growing revenues by 40%. Grow Funds highlights Paysign's potential for continued growth and capital returns to shareholders through dividends or share buybacks.
Number of shareholders of Paysign, Inc. – NASDAQ:PAYS
The article focuses on providing information about Paysign, Inc. (NASDAQ: PAYS), specifically mentioning the number of shareholders. It appears to be a stub or a placeholder page, as no specific shareholder numbers or related financial data are present. The content mainly consists of navigational elements and branding for TradingView and related financial data providers.
Paysign (PAYS) CLO granted 200,000 shares; 39,235 withheld for taxes
Paysign Inc.'s Chief Legal Officer, Robert Strobo, was granted 200,000 shares of performance-based restricted stock on November 13, 2025, following the achievement of an earnings target. On May 27, 2026, 39,235 shares were withheld by Paysign to cover tax obligations related to the vesting of this restricted stock. After these transactions, Strobo directly owns 488,055 shares of Paysign common stock, with the remaining restricted shares vesting in three equal annual installments through May 2028.
Paysign (PAYS) CEO logs stock grant and related tax withholding
Paysign, Inc. CEO Mark Newcomer received a grant of 400,000 performance-based restricted shares on November 13, 2025, after the company achieved an earnings target. Subsequently, on May 20, 2026, 78,701 shares were withheld at $6.15 per share to cover tax obligations related to the vesting of these restricted shares. Following these transactions, Newcomer directly holds 9,272,027 common shares of Paysign.
[Form 4/A] Paysign, Inc. Amended Insider Trading Activity
Paysign, Inc. EVP of Operations Joan M. Herman reported an amended open-market sale of 22,534 shares of common stock at a weighted average price of $7.0133 per share on May 26, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Herman directly holds 836,211 Paysign shares.
Paysign (PAYS) CPO reports 66,666-share award and tax withholding event
Paysign, Inc.'s Chief Payments Officer, Matthew Louis Lanford, reported equity compensation activity including a grant of 66,666 performance-based restricted shares. These shares will vest in equal installments on May 18, 2026, 2027, and 2028, with the performance goal already satisfied. Additionally, 12,755 shares were withheld on May 18, 2026, to cover tax obligations related to the vesting, leaving Lanford with 234,609 direct shares.
Paysign (PAYS) CFO logs 200,000-share performance award and tax withholding
Paysign, Inc.'s CFO, Jeffery Bradford Baker, reported receiving a 200,000-share performance-based restricted stock award on November 13, 2025, following the achievement of an earnings target. This award vests in three equal installments through May 30, 2028. Additionally, 44,541 shares were withheld on May 29, 2026, to cover tax obligations related to the vesting of restricted stock, leaving him with 541,677 shares directly held.
Paysign Inc (PAYS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Paysign Inc (PAYS) has an earnings forecast score of 8.80, ranking 9 out of 161 in its industry, with analysts setting an average price target of $9.00. The stock currently has a "Buy" rating from 5 analysts. Paysign's expected revenue for the next quarter is $26.35 million, and its EPS for the previous quarter was $0.02, with a forecast of $0.06 for the next quarter.
PAYS: Achieved 40.5% revenue growth and projects $106.5M–$110.5M in FY2026, balancing plasma and pharma
Paysign (PAYS) achieved a 40.5% revenue growth in FY2025, reaching $82M, and recorded $19.9M in adjusted EBITDA. The company, which holds 45.5% of the U.S. plasma market share, projects FY2026 revenue to be between $106.5M and $110.5M, driven by a balanced approach between its plasma and pharmaceutical segments.
Paysign (NASDAQ: PAYS) Form 144: insider files to sell 10,000 shares
A Paysign, Inc. Form 144 filing indicates a proposed sale of 10,000 shares of common stock by Bruce A. Mina, for an aggregate amount of $71,900. These shares originate from compensatory restricted stock grants awarded between 2018 and 2024. The filing serves as a notification of a planned resale by an affiliate, with a prior sale of 10,000 shares also noted in broker rows.
Paysign EVP Joan Herman sells $233,729 of PAYS stock By Investing.com
Paysign's EVP of Operations, Joan M. Herman, sold 29,202 shares of PAYS stock for approximately $233,729. This sale was conducted via a Rule 10b5-1 trading plan. Despite the insider sale occurring above the current trading price, InvestingPro analysis suggests the stock is undervalued, and the company recently reported strong first-quarter earnings for 2026.
Paysign EVP Joan Herman sells $233,729 of PAYS stock
Paysign EVP Joan Herman sold 29,202 shares of PAYS stock for approximately $233,729 at an average price of $8.0039 per share under a Rule 10b5-1 trading plan. This sale occurred despite the fact that the stock is currently trading below her sale price, though InvestingPro analysis suggests it remains undervalued with a PEG ratio of 0.7. The company recently reported strong Q1 2026 earnings, exceeding revenue and EPS forecasts, and DA Davidson reiterated a "Buy" rating with a $9.00 price target.
Executive Joan Herman sells 29,202 Paysign (PAYS) shares in planned trade
Paysign, Inc. EVP of Operations and Director, Joan M. Herman, sold 29,202 shares of common stock at a weighted average price of $8.0039 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Herman directly holds 807,009 shares of Paysign common stock.
Paysign EVP Joan Herman sells $233,729 of PAYS stock
Paysign's EVP of Operations, Joan M. Herman, sold 29,202 shares of PAYS stock for approximately $233,729 on June 1, 2026, under a Rule 10b5-1 trading plan. This transaction occurred despite the stock returning 71% over the past year, though the current trading price of $6.89 is below her sale price. InvestingPro analysis suggests the stock remains undervalued with a PEG ratio of 0.7.
Paysign, Inc. to Present at the Planet MicroCap Las Vegas 2026
Paysign, Inc. (NASDAQ: PAYS) announced its participation in the Planet MicroCap Las Vegas 2026 conference, scheduled for June 16-18, 2026. Jeff Baker, Paysign's CFO, is set to present on June 17 at 11:30 a.m. Pacific time. The company, which specializes in fintech and healthcare payment solutions for the life sciences industries, encourages investors to visit the event website for more details.
Paysign, Inc. to Present at the Planet MicroCap Las Vegas 2026
Paysign, Inc. (NASDAQ: PAYS), a provider of patient affordability programs and payment processing for life sciences, announced it will present at the Planet MicroCap Las Vegas 2026 conference. CFO Jeff Baker is scheduled to speak on Wednesday, June 17, at 11:30 a.m. Pacific time. The event brings together microcap investors, companies, and allocators.
Paysign EVP, operations Joan Herman sells $158k in stock
Joan M. Herman, EVP of Operations at Paysign, Inc. (NASDAQ:PAYS), sold 22,534 shares of company stock worth $158,037 on May 26, 2026, as part of a Rule 10b5-1 trading plan. This transaction follows Paysign's strong Q1 2026 results, which saw EPS and revenue surpass expectations, and a "Buy" rating maintained by DA Davidson. Despite the sale, Ms. Herman still holds over 813,000 shares, and the company's stock has shown significant gains over the past year.
Paysign (PAYS) CLO granted 66,667 performance shares; 39,235 withheld for taxes
Paysign's Chief Legal Officer, Robert Strobo, was granted 66,667 performance-based restricted shares on May 27, 2026, which vested upon the achievement of specific earnings targets. Concurrently, 39,235 shares were withheld by the company to cover tax obligations related to this vesting. Following these transactions, Strobo directly holds 393,957 shares of Paysign common stock, with the disposition being a tax-withholding mechanism rather than an open-market sale.
Paysign (PAYS) EVP Joan Herman sells 22,534 shares under 10b5-1 plan
Paysign, Inc.'s EVP of Operations and director, Joan M. Herman, sold 22,534 shares of common stock at a weighted average price of $7.0133 per share on May 26, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025. Following the sale, Herman still holds 813,989 shares of Paysign common stock, indicating the sale represents a small portion of her overall holdings.
PaySign, Inc. to Present at Barrington Research Virtual Spring Investment Conference
PaySign, Inc. announced its participation in the Barrington Research Virtual Spring Investment Conference. The company will present its operations and future strategies to investors and stakeholders. Further details regarding the presentation will be released closer to the conference date.
Paysign, Inc. to Present at the Barrington Research Virtual Spring Investment Conference
Paysign, Inc. (NASDAQ: PAYS) announced its participation in the 20th Annual Barrington Research Virtual Spring Investment Conference on May 27, 2026. Paysign's CFO, Jeff Baker, will be conducting one-on-one presentations throughout the day. The company specializes in integrated payment processing and program management for the life sciences industries, including patient affordability solutions and donor compensation programs.
Paysign, Inc. (PAYS) Presents at 20th Annual Barrington Research Virtual Spring Investment Conference - Slideshow
Paysign, Inc. (PAYS) presented at the 20th Annual Barrington Research Virtual Spring Investment Conference. This article provides the slide deck from their presentation. The content was published by SA Transcripts, Seeking Alpha's team dedicated to earnings call transcripts and other related projects.
Paysign, Inc. to Present at the Barrington Research Virtual Spring Investment Conference
Paysign, Inc. (NASDAQ: PAYS) announced its participation in the 20th Annual Barrington Research Virtual Spring Investment Conference. Jeff Baker, Paysign’s CFO, will be giving one-on-one presentations throughout the day on May 27, 2026. Paysign specializes in fintech and healthcare, providing patient affordability programs, donor compensation solutions, and integrated payment processing for life sciences industries.
PAYS - Paysign Inc. stock news, filings & ratings
Paysign Inc. (NASDAQ: PAYS) provides prepaid card products and processing services, specializing in healthcare-related payment solutions and donor compensation. The company recently reported strong financial results for Q1 2026, with revenue up 50.8% and pharma revenue increasing by 81.9% compared to Q1 2025. Insider transactions have included grants and sales of shares by key executives, and the company is actively presenting at investor conferences.
Paysign Inc. Surges on Strong Earnings Call
Paysign Inc. reported a strong Q1 earnings call with significant revenue growth of 50.8% year over year, reaching $28.0 million and exceeding guidance. The company highlighted robust pharma momentum, expanding margins, and strong cash generation, despite acknowledging some operational setbacks like plasma center closures and a higher tax rate. Paysign has also reaffirmed its full-year 2026 guidance, projecting continued growth in pharma and plasma businesses while actively managing costs.
Paysign (PAYS) CEO Mark Newcomer receives performance share award, withholds shares for taxes
Paysign Inc. CEO Mark Newcomer received an equity compensation award of 133,334 performance-based restricted shares, which vested on May 20, 2026, due to the achievement of specific earnings targets. To cover tax withholding obligations, 78,701 of these shares were disposed of back to the issuer at $6.15 per share. After these transactions, Newcomer's direct holdings increased to 9,084,062 shares of Paysign common stock.
Paysign (PAYS) CPO receives 22,222 share grant as restricted stock vests
Paysign, Inc.'s Chief Payments Officer, Matthew Louis Lanford, reported equity compensation activity where 22,222 performance-based restricted shares vested on May 18, 2026. To cover tax obligations, 12,755 shares were withheld by the company at $5.865 per share. After these transactions, Lanford directly holds 202,920 shares of Paysign common stock, reflecting compensation vesting and tax withholding rather than open-market trading.
Analysts Offer Insights on Technology Companies: PaySign (PAYS) and Salesforce (CRM)
Two technology companies, PaySign (PAYS) and Salesforce (CRM), have received bullish sentiments from analysts. PaySign was maintained with a Buy rating and a $8.50 price target by Gary Prestopino from Barrington, with an analyst consensus of Strong Buy and a $9.25 average price target. Salesforce received a Buy rating and a $240.00 price target from DBS analyst Andy Yu CFA, and generally holds a Moderate Buy consensus with a $255.88 average price target.
PAYS
Paysign, Inc. (PAYS) reported strong financial performance in Q1 2026, with revenue growing 50.8% to $28 million, exceeding guidance, and net income increasing 110% to $5.4 million. This growth was primarily driven by its patient affordability and plasma segments, with improved gross profit margins and increased income before taxes. The company provided optimistic full-year 2026 revenue guidance of $106.5 million to $110.5 million, highlighting confidence in continued growth despite some operational challenges and the absence of share repurchases.
Paysign (NasdaqCM:PAYS) Stock Forecast & Analyst Predictions
Paysign (PAYS) is forecast to achieve significant growth, with earnings and revenue expected to increase by 35.2% and 17.5% per annum, respectively. Recent guidance indicates strong performance in its pharma patient affordability segment, which is increasingly driving revenue growth. Analyst sentiment is generally positive, with several price target increases reflecting confidence in Paysign's profitability and scalability, despite some historical stock volatility and insider selling.
Assessing Paysign (PAYS) Valuation After Record Q1 Results And Patient Affordability Shift
Paysign (PAYS) recently reported record Q1 2026 results, driven significantly by its patient affordability business. Despite recent share price volatility, the stock has shown strong momentum historically. The article discusses Paysign's valuation, highlighting a "most popular narrative" that suggests the stock is undervalued with a fair value of $12.00, while also noting a higher P/E ratio compared to peers.
Is Paysign’s (PAYS) Affordability Shift Redefining Its Core Profit Engine?
Paysign, Inc. (PAYS) recently reported strong Q1 2026 results, with patient affordability programs becoming its largest revenue contributor, indicating a strategic shift towards higher-margin pharmaceutical offerings. This change in revenue mix is critical for its profitability and growth, reinforced by the company's 2026 guidance. While this shift diversifies Paysign away from plasma cards, investors should consider the associated execution risks and the concentration in a few healthcare segments.
Paysign (PAYS) EVP stock vests; shares withheld for taxes
Paysign, Inc. EVP of Operations, Joan M. Herman, had 11,111 shares of performance-based restricted stock vest on May 13, 2026. To cover tax obligations from this vesting, 6,171 shares were withheld by the issuer at $5.83 per share. These are routine compensation-related transactions, and after them, Herman directly holds 842,694 shares of Paysign common stock.
Is Paysign’s (PAYS) Affordability Shift Redefining Its Core Profit Engine?
Paysign's first-quarter 2026 results show a significant shift, with patient affordability programs becoming the largest revenue contributor, indicating a move towards higher-margin pharmaceutical offerings. This change supports the company's investment narrative of profitable growth through high-margin programs, despite potential risks from concentration in a few healthcare niches and rising costs. While the Q1 performance is strong and aligns with full-year guidance, investors should consider the execution risk associated with sustaining margins amid new investments.
PaySign, Inc. (NASDAQ:PAYS) Q1 2026 Earnings Call Transcript
PaySign, Inc. reported its strongest first quarter in company history for Q1 2026, with revenue growing 50.8% to $28 million and net income increasing 110% to $5.4 million. The patient affordability business saw significant growth, becoming the largest revenue contributor, while the plasma donor compensation business also showed a 25% increase in revenue. The company is confident in achieving the upper end of its 2026 guidance, driven by a robust pipeline in patient affordability and ongoing efficiencies in plasma operations.
Paysign projects 2026 revenue of $106.5M-$110.5M while targeting 147-150 active patient affordability programs by Q2
Paysign (NASDAQ: PAYS) announced its 2026 financial projections, targeting revenues between $106.5 million and $110.5 million. The company also aims to have 147 to 150 active patient affordability programs by the second quarter of 2026, signaling strong growth in its specialized segment. These projections highlight Paysign's strategic focus on expanding its presence in patient affordability solutions.
